Regenxbio's chart shows bullish signals with Bollinger Bands expanding upward.
ByAinvest
Monday, Sep 22, 2025 11:33 am ET1min read
RGNX--
The biotechnology company reported a loss of $1.38 EPS for the last quarter, significantly missing consensus estimates, with overall revenue coming in at $21.36 million compared to expected $40.87 million [1]. Despite the earnings miss, REGENXBIO's stock has experienced volatility, trading up 3.7% recently [1].
Analysts have mixed views on REGENXBIO's future prospects. Wall Street Zen cut the stock from a "hold" rating to a "strong sell" rating, while Chardan Capital and HC Wainwright reaffirmed a "buy" rating with price objectives of $52.00 and $34.00, respectively [1]. The consensus rating is "Moderate Buy" with a target price of $28.38 [1].
The 15-minute chart of REGENXBIO's stock exhibits an upward-expanding Bollinger Bands pattern, accompanied by a bullish Marubozu candle at 09/22/2025 11:30. This pattern indicates a dominant market trend driven by buyers, suggesting a continuation of bullish momentum .
Other institutional investors have also shown interest in REGENXBIO. FNY Investment Advisers LLC, Brooklyn Investment Group, Pallas Capital Advisors LLC, Entropy Technologies LP, and ProShare Advisors LLC have purchased new positions or increased their stakes in the company [1].
CEO Curran Simpson sold 7,734 shares of REGENXBIO stock, representing a 3.07% decrease in his position [1]. The company's market cap stands at $449.03 million, with a price-to-earnings ratio of -2.58 and a beta of 1.17 [1].
Regenxbio's 15-minute chart exhibits an upward-expanding Bollinger Bands pattern, accompanied by a bullish Marubozu candle at 09/22/2025 11:30. This indicates a dominant market trend driven by buyers, who are exerting control over the market, and suggests a continuation of bullish momentum.
Acadian Asset Management LLC has invested approximately $1.12 million in REGENXBIO Inc. (RGNX), acquiring 157,266 shares during the first quarter, which represents about 0.31% of the company [1]. This investment comes amid a mixed analyst sentiment, with ratings ranging from a "strong sell" to a "buy" rating and target prices between $17.00 and $52.00 [1].The biotechnology company reported a loss of $1.38 EPS for the last quarter, significantly missing consensus estimates, with overall revenue coming in at $21.36 million compared to expected $40.87 million [1]. Despite the earnings miss, REGENXBIO's stock has experienced volatility, trading up 3.7% recently [1].
Analysts have mixed views on REGENXBIO's future prospects. Wall Street Zen cut the stock from a "hold" rating to a "strong sell" rating, while Chardan Capital and HC Wainwright reaffirmed a "buy" rating with price objectives of $52.00 and $34.00, respectively [1]. The consensus rating is "Moderate Buy" with a target price of $28.38 [1].
The 15-minute chart of REGENXBIO's stock exhibits an upward-expanding Bollinger Bands pattern, accompanied by a bullish Marubozu candle at 09/22/2025 11:30. This pattern indicates a dominant market trend driven by buyers, suggesting a continuation of bullish momentum .
Other institutional investors have also shown interest in REGENXBIO. FNY Investment Advisers LLC, Brooklyn Investment Group, Pallas Capital Advisors LLC, Entropy Technologies LP, and ProShare Advisors LLC have purchased new positions or increased their stakes in the company [1].
CEO Curran Simpson sold 7,734 shares of REGENXBIO stock, representing a 3.07% decrease in his position [1]. The company's market cap stands at $449.03 million, with a price-to-earnings ratio of -2.58 and a beta of 1.17 [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet